drug development

ChemRegen is a regenerative medicine research and development company located in San Diego, California, combining stem cell biology and drug development. Its initial technology is based on work done in collaboration between Dr. Mark Mercola of the Sanford Burnham Research Institute and Dr. John Cashman of the Human BioMolecular Research Institute, who also serves as Chief Operating Officer of ChemRegen. ChemRegen provides design, implementation, and interpretation of pre-clinical regenerative medicine drug development.

pre-clinical drug developmentregenerative medicine researchstem cell biology

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in adjunct cancer care, oncology, stem cell therapy and unique prescription products. LYMPHIR (denileukin diftitox-cxdl), a targeted immune therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), is approved by the FDA.

clinical trialsdevelopment and commercialization of critical care productsmanufacturingstem cell therapy

CMTx Biotech, Inc. is a Stony Brook, NY company developing medical countermeasures against high priority CBRN threats. It pursues drug rescue and repositioning, including new therapeutic uses and formulations of clinical stage drug candidates and of drugs already approved for human use. Its science focuses on host-directed therapeutics (HDTs) targeting hyper-inflammatory and dysregulated immune responses to infection, insult, or injury. Lead candidate incyclinide has completed IND-enabling studies; CMTx R2 is an STS protein inhibitor advanced for host-di

drug repurposinghost-directed therapeuticsIND-enabling studiesmanufacturingtechnology commercialization and licensing

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company developing oral medications designed to treat neurodegenerative disorders. Its lead candidate, zervimesine (CT1812), is an investigational first-in-class small-molecule oral therapy designed to protect brain synapses by blocking toxic protein oligomers, and is being investigated for dementia with Lewy bodies (DLB) and Alzheimer's disease.

clinical trialsmanufacturing oversightprocess developmentquality control

Common Pharma, Inc. is a pharmaceutical company developing medicine for hard-to-treat diseases. Its primary focus is a novel class of compounds with preclinical effectiveness in treating xenograft tumors and blocking IL-6 overexpression. Its patented molecules have shown anti-bacterial efficacy against P. Acne and MRSA, and it has a topical program for dermal conditions with clinical efficacy in reducing facial blemishes.

clinical trialspreclinical research

Constant Therapeutics LLC is a private biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System. It develops peptide and small molecule drugs, including its lead peptide product TXA127, a pharmaceutical formulation of the natural human peptide angiotensin-(1-7). The company targets diseases with significant unmet needs including Duchenne Muscular Dystrophy, Epidermolysis Bullosa, and Ischemic Stroke.

clinical trials

Cortene is a clinical stage biopharmaceutical company developing a patent-protected, peptide-based treatment for brain-centric acquired chronic diseases (ACDs). Its hypothesis centers on dysregulated serotonin signals driven by upregulated CRFR2, which it aims to reverse using agonist-mediated receptor endocytosis. The hypothesis has been partially proven in a proof-of-concept Phase 2 clinical trial, and the company plans trials in Parkinson's and Alzheimer's.

clinical trialspeptide manufacturing and formulationRegulatory Affairs

Corvidane is a privately held life sciences company developing novel therapeutic approaches for cardiometabolic disease, including atherosclerosis and metabolic dysfunction associated steatohepatitis (MASH). Its lead programme, CVMB-216, is a patented orally administered, multi-pathway therapeutic that activates a spectrum of clinically validated targets spanning lipid metabolism, inflammation and fibrosis. The company advances programmes through structured preclinical development toward regulated clinical pathways and pursues two indications for FDA app

clinical developmentpreclinical developmentprocess scale-uptherapeutic developmenttranslational research

Crinetics Pharmaceuticals, Inc. is a global pharmaceutical company focused on discovery, development, and commercialization of novel therapeutics for endocrine disease and endocrine-related tumors. Its in-house R&D team develops novel molecules targeting the endocrine system and G-protein coupled receptors. The company aims to build the world's leading endocrine company.

commercializationdrug discoveryGPCR-targeted drug discoveryR&D

Cumberland Pharmaceuticals Inc. is an innovation-driven biopharmaceutical company based in Nashville, Tennessee, and publicly listed on Nasdaq under CPIX. For over 25 years it has improved patient care through the delivery of high-quality prescription medicines, and it develops new therapies addressing significant unmet medical needs.

biopharmaceutical developmentclinical trials

Curlim is a biotech company founded in 2024 as a spin-off from the University of Limoges, bringing together three PhD scientists and a C-level business person to address unmet needs in neurology, specifically hereditary peripheral neuropathies. Its first mission is developing CLM001, a nanomedicine for Charcot-Marie-Tooth disease type 1A (CMT1A), the most common inherited peripheral neuropathy.

nanotechnologypreclinical studies

Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology. It discovers, develops, and commercializes potential medicines for diseases of impaired muscle function, including heart failure, hypertrophic cardiomyopathy (HCM), and neuromuscular diseases such as ALS. Its research focuses on modulating proteins in the sarcomere, including myosin and troponin, and it has a pipeline of small molecule muscle activators and inhibitors.

clinical trialscommercialization of medicinesdrug discoverymuscle biology research

Danmir Therapeutics, LLC is an emerging biopharmaceutical company focusing on novel therapeutic approaches based on pharmacologic manipulation of P2 receptors' signal transductions activated by extracellular adenosine 5'-triphosphate (ATP). Its lead drug candidate DT-0111 (Aspirex) is a water-soluble selective P2X2/3 receptor antagonist in development as an inhalation drug for COPD and chronic cough. The company was founded in 2008 by Amir Pelleg, Ph.D.

inhalation drug developmentoral drug formulationpharmacologic manipulation of P2 receptor signal transductions

Day One Biopharmaceuticals is a biopharmaceutical company focused on advancing first- or best-in-class targeted medicines for childhood and adult diseases, particularly cancer. Founded to address the lack of new therapies from the traditional drug development model, it develops new medicines for people of all ages with life-threatening diseases. The company is now part of Servier Group and is based in Brisbane, California.

clinical trialsoncology research

Debiopharm is an independent biopharmaceutical company based in Switzerland, committed to developing tomorrow's standard of care to cure cancer and infectious diseases and improve patient quality of life. Its main activities include drug development, drug manufacturing and digital health investment. Founded in 1979 by Dr. Rolland-Yves Mauvernay, it is now a group of three companies: Debiopharm International (drug development), Debiopharm Research & Manufacturing (drug manufacturing) and Debiopharm Innovation Fund (digital health investment). It is the Li

digital health investmentdrug manufacturingin-licensing and out-licensing of compoundsresearch & development

Dehealth LLC is a consulting firm serving the pharmaceutical and life sciences sectors. It provides expertise in injectables development, pharmaceutical lifecycle support (drug development, upscale, CMO sourcing, TechTransfer, commercialization, SCM, and regulatory/quality demands across ICH regions), medical device registration and development including risk classification, technical documentation, CE roadmaps, and authority liaison in the USA and EU, and food supplement product establishment including formulation, raw material and packaging selection,

CE roadmapCMO sourcingcommercializationfood supplement formulationHACCPinjectables developmentmedical device registrationpharmaceutical consultingregulatory/quality supportrisk classificationSCMtechnical documentationTechTransfertraining programsupscaleworkshops

DemeRx is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of addiction. It is developing DMX-1001 (oral noribogaine), an investigational therapy for alcohol use disorder, which affects over 29 million people in the U.S. The company was founded on the research of Dr. Deborah Mash on the neuroplastogen noribogaine, the active metabolite of ibogaine, aiming to restore and reset the brain's addiction circuitry.

clinical developmentneuroscience research

Dialectic Therapeutics is a clinical-stage biotechnology company based in Dallas, Texas, dedicated to developing innovative anti-cancer drugs. Its lead candidate, DT2216, is built on its proprietary Antiapoptotic Protein Targeted Degradation (APTaD™) technology platform and selectively induces cancer cells to degrade BCL-XL. DT2216 is in Phase 1/2 clinical trials for Fibrolamellar Carcinoma and Platinum-Resistant Ovarian Cancer.

clinical trialsmedicinal chemistryprotein degradation

Diastol Therapeutics is an emerging biotechnology company developing a treatment for Heart Failure with Preserved Ejection Fraction (HFpEF) as its lead program. Founded in 2018, it is located in Chicago, IL/Minneapolis, MN, and aims to build a cardiovascular-focused company treating leading causes of death and morbidity. Its lead drug candidate is a first-in-class compound with a validated target, with ongoing non-human primate studies and IND filing planned within 18 months of financing.

clinical trialsCMC and tox studiesnon-human primate studiesPD assays

Double Bond Pharmaceutical is a pharmaceutical company founded in 2014 by Dr. Igor Lokot that develops and commercializes innovative first-in-class treatments for cancers and infectious diseases. It focuses on redeveloping known drugs by changing the route of administration to create new formulations that reduce side effects and improve efficacy, with expertise in brain cancer, liver cancer and pneumonia.

AI-driven drug discoveryclinical researchdrug delivery systemsreformulation of known drugs

Dynamiko Pharmaceutics, LLC is dedicated to providing and developing anti-cancer therapies that are selective and potentially more effective therapeutics. Its mission is to offer lifesaving therapeutic alternatives to cancer patients that improve survivorship outcome and quality of life, focusing on the discovery and development of selective and targeted drugs. Its innovation stems from identifying nature-derived compounds that show selectivity against cancer cells and are safe for healthy tissue.

drug discoverynatural product screeningsynthesis and modification of natural products

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company that discovers, develops, and markets medicines for patients, healthcare providers, and health systems. Its portfolio includes Byfavo (remimazolam) for procedural sedation and Pemfexy (pemetrexed injection) for non-small cell lung cancer and malignant pleural mesothelioma. The company describes a first-in-class new chemical entity pipeline with product candidates across oncology and critical care.

marketing of medicinespharmaceutical discovery

EdenRoc Sciences, LLC is a life sciences portfolio company focused on addressing the diseases of aging, with assets ranging from genomic detection to clinical stage pharmaceuticals, forensics and biologic-based consumer products. It founds subsidiaries based on novel science, often intellectual property licensed from top universities, and supports them with shared core business functions. The company is driven by a team of over 100 scientists and staff with support from over 40 advisors.

forensic DNA sequencing and genotypinggenomic detectionmicroarray design and fabricationnext-generation sequencing (NGS)RNA synthesis

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapies for life-threatening acute respiratory and critical care conditions. Its lead drug candidate, ENA-001, is a patent-protected new chemical entity with a novel mechanism of action, beginning additional clinical trials in the fourth quarter of 2021, targeting conditions such as drug overdose respiratory depression and apnea of prematurity. The company is located in Rowan University's Samuel H. Jones Innovation Center in Mullica Hill, NJ.

clinical trials